Further, several monoclonal antibodies (mAbs) against TROP2 are currently evaluated in clinical cancer trials, including DS-1062a [4,11], PF-06664178 [4,12], and IMMU-132 [4,13,14]. This evidence concerns the gene TACSTD2 and cancer.